Results 61 to 70 of about 19,061 (206)

Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China

ClinicoEconomics and Outcomes Research
Wenjuan Wang,1,* Dachuang Zhou,1,* Kejia Zhou,1 Di Zhang,1 Hao Li,1 Hongliu Zhang,1 Xin Jiang,1 Ruihua Wang,1 Xi Wang,2 Wenxi Tang1 1Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu ...
Wang W, Zhou D, Zhou K, Zhang D, Li H, Zhang H, Jiang X, Wang R, Wang X, Tang W   +9 more
doaj  

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source

A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis

European Journal of Neurology, Volume 33, Issue 2, February 2026.
This was a national multicenter comparative effectiveness research study using data from the Danish Multiple Sclerosis Registry. Relapsing–remitting multiple sclerosis patients initiating ocrelizumab or natalizumab between January 2018 to April 2023 were included.
Camilla Maersk‐Moller, Luigi Pontieri, Morten Leif Munding Stilund, Jeppe Romme Christensen, Lars Kristian Storr, Victoria Hansen, Jakob Schäfer, Arkadiusz Weglewski, Katerina Quinto Romani, Henrik Boye Jensen, Zsolt Illes, Victoria Papp, Tobias Sejbaek, Mai Bang Poulsen, Matthias Kant, Caroline Winther Torring, Finn Sellebjerg, Melinda Magyari, The DMSG Group   +18 more
wiley   +1 more source

Navigating Healthcare Economics Optimizing Therapeutic Efficacy and Cost with Pharmacoeconomics

Journal of Pharmacoeconomics and Pharmaceutical Management
Background:  In today's healthcare landscape, escalating costs underscore the pressing need for pharmacoeconomic evaluations, particularly in low- and middle-income countries (LMICs) where medication expenses can dominate healthcare budgets ...
Rania Indu, Moumita Ray, Sudipto Mangal
doaj  

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

Рациональная фармакотерапия в кардиологии, 2018
Aim. To perform pharmacoeconomic analysis of CHF therapy with supramolecular sacubitril/valsartan complex compared to routine therapy in patients with diabetes type 2 and ACE inhibitor intolerance within context of Russian healthcare system.Material and ...
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov   +2 more
doaj   +1 more source

The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 1, Page 24-32, January 2026.
Abstract Objectives Multiorgan abdominal involvement is a hallmark of Cystic fibrosis (CF). The CFAbd‐Score© is the first CF‐specific gastrointestinal patient reported outcome‐measure (PROM) developed following FDA‐guidelines. The PROM has proved to sensitively differentiate people with CF (pwCF) from healthy controls (HC).
Isabelle Sermet‐Gaudelus, Pauline Sadrieh, Anne Sophie Bonnel, Raphael Enaud, Nathalie Wizla, Jeanne Languepin, Ambre Nangui, Audrey Deelawon, Johanna Rave, Samira Dabelow, Anton Barucha, Carlos Zagoya, Franziska Duckstein, Jochen Georg Mainz   +13 more
wiley   +1 more source

Pharmacoeconomics of Bronchial Asthma

Folia Medica, 2019
Introduction: Pharmacoeconomics (PE) treats the problems of pharmacotherapy policy, drug marketing and reimbursement and clinical trials. It guides policy makers for effective health resources utilization and determines the profitability of the new drugs
Ivanova Zlatina I., Ivanov Yavor Y.
doaj   +1 more source

Stigma, Scarcity and the Price of Legitimacy: Chronic Pain Advocacy and the Politics of Pharmaceutical Partnerships in Canada

Sociology of Health &Illness, Volume 48, Issue 1, January 2026.
ABSTRACT This study examines how chronic pain advocates in Canada navigated fraught relationships with pharmaceutical companies amid escalating concerns about the adverse public health impacts of opioids. Drawing on 22 qualitative interviews with professional chronic pain advocates, it examines how advocates navigated their complex relationships with ...
Daniel Eisenkraft Klein, Benjamin Hawkins, Quinn Grundy, Robert Schwartz   +3 more
wiley   +1 more source

Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma

Multidisciplinary Respiratory Medicine, 2018
After publication of the Original research article [1] it was brought to our attention that the sentence at pag 6 (between Figure 3 and Figure 4)) must be corrected as follows: “The mean duration of inactivity was 2.88 (0.63) at baseline; 1.53 (0.27 ...
Roberto W. Dal Negro, Luca Bonadiman, Paola Turco   +2 more
doaj   +1 more source

Editorial [Pharmacoeconomics & Health Economics: Opening Access to Science and Practice] [PDF]

, 2009
Steven Simoens
openalex   +1 more source